Drug Search Results
More Filters [+]

Fibrin

Alternative Names: fibrin, tisseel, crosseal, evicel, artiss, tachosil, evarrest, raplixa, vistaseal
Latest Update: 2025-01-17
Latest Update Note: Clinical Trial Update

Product Description

Mechanisms of Action: Fibrinolysis Agonist

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Topical,Injection

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: Australia | Austria | Belgium | Brazil | Bulgaria | Canada | China | Colombia | Croatia | Czech | Denmark | France | Germany | Greece | Hong Kong | Hungary | India | Ireland | Italy | Jordan | Lebanon | Lithuania | Luxembourg | Malaysia | Malta | Mexico | New Zealand | Norway | Poland | Singapore | Slovenia | Spain | Sweden | Taiwan | Turkey | United Arab Emirates | United Kingdom | United States | Uruguay

Approved Indications: None

Known Adverse Events: None

Company: Ethicon
Company Location:
Company CEO:
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Fibrin

Countries in Clinic: Australia, Bulgaria, Canada, China, France, Germany, Hungary, Romania, Serbia, Spain, Sweden, United Kingdom, United States

Active Clinical Trial Count: 12

Highest Development Phases

Phase 3: Adenocarcinoma|Cardiac Arrest|Gastrointestinal Cancer|Injuries/wounds Unspecified

Phase 2: Diabetic Foot|Intervertebral Disc Degeneration

Phase 1: COVID-19

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

2024-513151-33-00

P2

Unknown Status

Unknown

2027-06-22

2019-004657-89

P3

Unknown status

Cardiac Arrest

2025-12-14

CM-TS01

P3

Not yet recruiting

Injuries/wounds Unspecified

2025-07-31

BIOS-16-001

P3

Recruiting

Cardiac Arrest

2025-06-01

Recent News Events